Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic polymer-encapsulated IL-2-secreting retinal pigmented epithelial cells AVB-001

A preparation of polymer-encapsulated cells, obtained from the human immortalized retinal pigment epithelia (RPE) cell line ARPE-19, that have been genetically engineered to express the human cytokine interleukin-2 (IL-2; IL2), with potential immunomodulatory and antineoplastic activities. Upon intraperitoneal administration, allogeneic polymer-encapsulated IL-2-secreting RPE cells AVB-001 produces IL-2 locally, which binds to the IL-2 receptor (IL-2R) and activates IL-2/IL-2R-mediated signaling. This activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This leads to T-cell-mediated cytotoxic immune responses against tumor cells and inhibition of tumor cell proliferation. The local delivery of AVB-001 reduces systemic toxicities, and the polymer encapsulation allows for longer half-life.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic polymer-encapsulated IL-2-secreting RPE cells AVB-001
Code name:AVB 001
AVB-001
AVB001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search